Life Sciences Times, Author at Boston Life Sciences Times

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

December 13, 2025

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

December 12, 2025

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

December 11, 2025

THIS WEEK'S STORIES

Zai Lab Begins Global Phase 1/1b Trial of ZL-1503 for Atopic Dermatitis

December 8, 2025

Montagu and Kohlberg Agree to Acquire Teleflex Medical OEM for $1.5 Billion

December 9, 2025

Charles River extends incubator program with second global cohort

December 11, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Life Sciences Times

TOP AUTHORS

Most Read

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

Acadia Pharmaceuticals Wins FDA Approval for DAYBUE STIX Powder Formulation for Rett Syndrome

ImmunityBio Wins EMA Recommendation for Conditional Approval of ANKTIVA With BCG for Bladder Cancer

Cosette Pharmaceuticals Terminates Agreement to Acquire Mayne Pharma

EDITOR PICKS

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

THIS WEEK'S STORIES

Zai Lab Begins Global Phase 1/1b Trial of ZL-1503 for Atopic Dermatitis

Montagu and Kohlberg Agree to Acquire Teleflex Medical OEM for $1.5 Billion

Charles River extends incubator program with second global cohort

POPULAR CATEGORY

ABOUT US

FOLLOW US